

Pentafluorosulfanyl (SF₅) as a Superior ¹⁹F Magnetic Resonance Reporter Group: Signal Detection and Biological Activity of Teriflunomide Derivatives

Christian Prinz, Ludger Starke, Tizian-Frank Ramspoth, Janis Kerkering, Vera Martos Riaño, Jérôme Paul, Martin Neuenschwander, Andreas Oder, Silke Radetzki, Siegfried Adelhoefer, Paula Ramos Delgado, Mariya Aravina, Jason M. Millward, Ariane Fillmer, Friedemann Paul, Volker Siffrin, Jens-Peter von Kries, Thoralf Niendorf, Marc Nazaré, and Sonia Waiczies*



Cite This: *ACS Sens.* 2021, 6, 3948–3956



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Fluorine (¹⁹F) magnetic resonance imaging (MRI) is severely limited by a low signal-to noise ratio (SNR), and tapping it for ¹⁹F drug detection in vivo still poses a significant challenge. However, it bears the potential for label-free theranostic imaging. Recently, we detected the fluorinated dihydroorotate dehydrogenase (DHODH) inhibitor teriflunomide (TF) non-invasively in an animal model of multiple sclerosis (MS) using ¹⁹F MR spectroscopy (MRS). In the present study, we probed distinct modifications to the CF₃ group of TF to improve its SNR. This revealed SF₅ as a superior alternative to the CF₃ group. The value of the SF₅ bioisostere as a ¹⁹F MRI reporter group within a biological or pharmacological context is by far underexplored. Here, we compared the biological and pharmacological activities of different TF derivatives and their ¹⁹F MR properties (chemical shift and relaxation times). The ¹⁹F MR SNR efficiency of three MRI methods revealed that SF₅-substituted TF has the highest ¹⁹F MR SNR efficiency in combination with an ultrashort echo-time (UTE) MRI method. Chemical modifications did not reduce pharmacological or biological activity as shown in the in vitro dihydroorotate dehydrogenase enzyme and T cell proliferation assays. Instead, SF₅-substituted TF showed an improved capacity to inhibit T cell proliferation, indicating better anti-inflammatory activity and its suitability as a viable bioisostere in this context. This study proposes SF₅ as a novel superior ¹⁹F MR reporter group for the MS drug teriflunomide.

KEYWORDS: SF₅, teriflunomide, DHODH, fluorine, MRI, MRS



More than one-third of prescribed drugs contain fluorine (¹⁹F), which generally improves their pharmacokinetic properties.^{1–5} Fluorination also opens an opportunity to noninvasively study drugs in vivo using ¹⁹F magnetic resonance imaging (MRI). This prospect heralds an age when exact locations and concentrations of drugs can be determined in patients to inform drug therapies.^{2–8} The signal-to-noise ratio (SNR) achieved with ¹⁹F MRI is limited because of the low availability of ¹⁹F nuclei in vivo. Additionally, specific ¹⁹F magnetic resonance (MR) properties (chemical shift, spectral shape, e.g., full width at half maximum or FWHM, spin–lattice (T₁) and spin–spin (T₂) relaxation times) and pharmacological properties (metabolism, protein binding, etc.) could influence SNR and ¹⁹F MR signal detection.

The application of ¹⁹F MRI continues to expand, e.g., to track immunotherapies,⁹ investigate temperature-dependent molecular switches,¹⁰ image tumors using pH-responsive probes,¹¹ or monitor inflammatory processes in vivo.^{12,13} The implications of


¹⁹F MR methods to study physiological, enzymatic, and other metabolic processes in vitro and in vivo have long been recognized.^{1,14} Molecular modifications involving introduction of ¹⁹F side groups have served several purposes, e.g., as diagnostic biomarkers, where ¹⁹F tracers or contrast agents are implemented to interrogate function in biological systems.¹

Fluorinated drugs can be detected in vivo using ¹⁹F MR spectroscopy (MRS) methods.¹⁵ Recently, we detected teriflunomide (TF), a dihydroorotate dehydrogenase (DHODH) inhibitor, in an animal model of multiple sclerosis

Received: May 17, 2021

Accepted: September 24, 2021

Published: October 20, 2021



(MS) using nonlocalized ^{19}F MRS.¹⁶ TF inhibits the mitochondrial DHODH enzyme that catalyzes the synthesis of the pyrimidine nucleotide precursor orotate necessary for DNA replication, including CNS-specific T cells that are key players in the MS pathology, thereby exerting its anti-inflammatory action in MS.¹⁷ Despite recent advances to improve radiofrequency coil sensitivities,¹⁸ there are still limitations that impede detection of ^{19}F drugs in vivo with ^{19}F MRI or localized ^{19}F MRS, while these methods will be essential to locate drugs within specific tissue and study their distribution in vivo. SNR was a major limitation in our previous study due to the low TF availability in vivo, thereby prohibiting imaging or localized MRS to specify its location in vivo.¹⁶

The pentafluorosulfanyl (SF_5) group has gained an immanent role in organic materials, polymers, and liquid crystals and has also recently emerged as a bioisostere for lipophilic groups like CF_3 , *tert*-butyl, halogen, or nitro groups in biologically active compounds.¹⁹ SF_5 has been studied extensively in the gas phase as a diagnostic tool for pulmonary ^{19}F MRI.^{20–25} However, surprisingly, the corresponding derived organic $-\text{SF}_3$ group has thus far not been investigated as a ^{19}F MRI reporter group.

In this study, we investigated different modifications to the CF_3 group of TF. This included the addition of two symmetrical CF_3 groups to increase the number of ^{19}F atoms and the introduction of a SF_5 group and a trifluoromethoxy-group to probe the effects of altering the chemical environment of ^{19}F atoms while leaving their number constant, to improve their SNR and promote drug monitoring in vivo. In parallel, we also aimed to preserve or even improve the pharmacological activity of TF. Generally, the introduction of fluorine substituents enhances the potency of DHODH inhibition of TF.²⁶ Here, the CF_3 group plays an important role in stabilizing the bioactive conformation of TF.²⁷ The SF_5 group can be considered a bioisostere of CF_3 -groups in drug compounds.²⁸ After a thorough characterization of the pharmacological properties and ^{19}F MR properties of the synthesized derivatives, we selected and optimized suitable MR sequences, compared their SNR efficiency in imaging the derivatives, and aligned this with their capacity to inhibit T cell proliferation. Ultimately, we selected the best suited candidate for an ex vivo demonstration of ^{19}F MRI in the murine stomach.

EXPERIMENTAL SECTION

Synthesis of TF and Its Derivatives. Fluorinated anilines were coupled with isoxazol acid chloride by a Schotten–Baumann reaction,^{29,30} and the isoxazol ring of the resulting leflunomide prodrug structure was hydrolyzed for conversion into the teriflunomide derivatives³¹ (Supporting Information: Chemistry, Figure S1). Derivatives of TF (Figure 1) resulted from a substitution of the *para* CF_3 -group on the benzene ring with a trifluoromethoxy $\text{CF}_3\text{O-R}$ group, two chemically symmetrical *meta* CF_3 groups, and one *para* pentafluorosulfanyl SF_5 group.

Pharmacological Activity. The inhibitory activity of TF derivatives on the DHODH enzyme was measured with a colorimetric enzyme activity assay. Drug concentration ranged from 50 μM serially diluted in DMSO to 4.9 nM with a final DMSO concentration of 1%. DHODH inhibition was studied by monitoring the reduction of 2,6-dichloroindophenol (DCIP) (Alfa Aesar) via color change (blue to colorless, loss of absorbance at 620 nm). The colorimetric reaction is associated with the oxidation of L-dihydroorotate (L-DHO) (Alfa Aesar) that is catalyzed by the DHODH enzyme.^{32–35} The reaction was performed in duplicate in volumes of 30 μL in a 384-well plate in 50 mM tris–HCl buffer, containing 73 nM coenzyme Q10 (Selleckchem), 0.1% Triton X-100 (Sigma-Aldrich), 150 mM KCl (Sigma-Aldrich), 211 nM DCIP (Thermo Fisher), and 7.5 nM DHODH (Biozol). The




Figure 1. Chemical structures of the synthesized teriflunomide derivatives.

reaction was started by the addition of the substrate L-DHO, performed at 30 °C, and monitored over 60 min using a Tecan Safire2 Multimode Microplate Reader (Tecan).

Biological Activity. The inhibitory activity of TF derivatives on T cell proliferation was studied after isolating peripheral blood mononuclear cells (PBMCs) from healthy volunteers. Informed, signed consent was obtained for collecting blood samples. Approval was granted from the ethics commission of the Charité (EA1/023/15). Compounds were dissolved in DMSO (19 mM) and further diluted to final concentrations ranging from 0.39 to 50 μM .³⁶ Compounds (10 μL) were plated on 96-well plates and stored at 4 °C.

Blood (in EDTA) was withdrawn from two male healthy volunteers (aged 25–35), diluted 1:2 in PBS, and layered on Lymphopure (BioLegend) for separating cell populations using the principle of Ficoll density gradient centrifugation (764 g, 40 min, RT, no brake). PBMCs were cautiously collected from the corresponding phase and diluted in PBS. After two washing steps in PBS, the cell pellet was resuspended in a HEPES–RPMI 1640 buffer and counted using a Neubauer cell-counting chamber.

Isolated PBMCs were labeled with carboxyfluorescein succinimidyl-ester (CFSE) (BioLegend) as described elsewhere.³⁷ The fluorescent dye CFSE is taken up into the cells. Dilutions of CFSE in daughter cells (1:2 as a result of cell division) result in sequential losses in fluorescence intensities. Labeling was performed according to the manufacturer's descriptions using 5 μM CFSE, and staining was quenched using a medium containing 10% FCS. Cells were recounted and resuspended in a cell culture medium (5% human AB serum, 1% GlutaMax ($\times 100$, Gibco), 10 mM HEPES (Gibco), and 1% penicillin (10 U/ μL)/streptomycin (10 $\mu\text{g}/\mu\text{L}$) (Gibco) in an RPMI 1640 medium (Gibco) at a concentration of 10^6 cells/mL. To induce T cell proliferation, isolated PBMCs were incubated with the superantigen-similar polyclonal stimulating reagent CytoStim (Miltenyi Biotec) following the manufacturer's instructions. CytoStim was added to the cell suspensions (0.2%).

Cells with or without CytoStim were distributed in 96-well plates (in triplicate, with final volumes of 200 μL per well) and kept at 37 °C and 5% CO_2 for 72 h. Wells without DHODH inhibitors (TF or its derivatives) served as positive proliferation controls, and wells without T cell stimuli and inhibitors served as negative controls. After incubation, cells were centrifuged, washed with PBS, and resuspended in FACS buffer (0.5% BSA and 0.1% NaN_3 (Sigma-Aldrich) in PBS). Propidium iodide (PI) (BioLegend) was added to each well approximately 5 min before the measurement to stain the dead cell population. The fluorescence of CFSE labeling and PI staining was analyzed by flow cytometry using a BD LSRFortessa flow cytometer (BD Biosciences).

MR Methods. MR experiments were performed on a 9.4 T MR scanner (Bruker Biospec, Ettlingen, Germany). All DHODH inhibitors (TF or its derivatives) were diluted in either 100% DMSO (Roth) or 100% human serum. The human serum was prepared from whole blood withdrawn from a male healthy volunteer (aged 25) and allowed to stand for 15–30 min at room temperature; following centrifugation (21.1 g, 10 min, RT), the supernatant (serum) was transferred into a

new container. Serum samples were stored at $-20\text{ }^{\circ}\text{C}$. Phantoms were prepared in 2 and 1 mL syringes to characterize the spectra, chemical shifts, relaxation times, and signal-to-noise (SNR) efficiencies. Teriflunomide (Sigma-Aldrich and Genzyme) was used as a reference compound. Concentrations of the compounds were adjusted as indicated in Table S1.

For phantom experiments, a home-built dual-tunable $^{19}\text{F}/^1\text{H}$ mouse head RF coil was used.¹² MR measurements were performed at room temperature (RT).

A global single pulse spectroscopy (TR = 1000 ms, TA = 8 s, nominal flip angle (FA) = 90° , block pulse, 4096 points, dwell time = 0.02 ms, excitation pulse = 10,000 Hz, spectral bandwidth = 25,000 Hz) was used to detect the ^{19}F signal and to make frequency adjustments. Chemical shifts are referenced to trichlorofluoromethane, CFCl_3 ($\delta_{\text{F}} = 0$ ppm).

For determining T_1 in low concentrated serum samples, global spectroscopy with different TRs (TR = 50–8000 ms) was used. For spectroscopically determining T_2 , a CPMG sequence was used (TR = 5000 ms, 25 echoes, echo spacing = 2.8 ms, excitation pulse = 5000 Hz, spectral bandwidth = 25,000 Hz).

T_1 mapping was performed using RARE (rapid acquisition with relaxation enhancement): TE = 4.6 ms, echo train length (ETL) = 4, FOV = $[16 \times 16]$ mm², matrix size = 64×64 , with 9 variable repetitions times (TR = 25–8000 ms). T_2 mapping was performed using a multislice multiecho sequence: TR = 2000 ms, FOV = $[16 \times 16]$ mm², matrix size = 64×64 , with 25 different TEs (TE = 40–1000 ms in steps of 40 ms for long T_2 and TE = 8–200 ms in steps of 8 ms for short T_2).

To determine the most SNR efficient MR technique for acquiring ^{19}F MRI of TF and its derivatives, we optimized the parameters (Table S3) of three MR sequences: RARE, bSSFP (balanced steady-state free precession), and UTE (ultrashort echo time). For all methods, the image geometry was set to FOV = $[28 \times 28]$ mm², matrix size = 96×96 in DMSO, matrix size = 64×64 in serum, and slice thickness = 5 mm. Pulse sequence parameters were optimized based on the relaxation times of each compound in DMSO and serum.^{38,39}

For RARE, the receiver bandwidth was set to 10 kHz to maximize SNR but limit chemical shift artifacts. Centric encoding was used, and the echo spacing was kept minimal for both long T_2 conditions, i.e., in DMSO ($\text{TE}_{\text{DMSO}} = 12.12$ ms), and short T_2 conditions, i.e., in serum ($\text{TE}_{\text{serum}} = 2.29$ ms). For the latter condition, a RARE sequence with gradient pulses optimized for short echo spacing (RAREst) was used. We used a flip-back module and, based on simulations, chose the highest possible ETL with a full width at half maximum (FWHM) of the point spread function (PSF) below 1.5 pixels. Given these parameters, we optimized the repetition time (TR) based on the steady state signal intensity equation.³⁸

For bSSFP, the receiver bandwidth was set to 100 kHz to achieve a short TR = 2.6 ms (TE = 1.3 ms) and thus stability regarding banding artifacts. For each compound and condition, the flip angle α_{bSSFP} was adjusted to

$$\alpha_{\text{bSSFP}} = \arccos\left(\frac{T_1 - T_2}{T_1 + T_2}\right)$$

For UTE, we used an FID readout (TE = 0.27 ms) and a read bandwidth of 20 kHz. We used TR = 100 ms and the calculated Ernst angle α_{E} as the flip angle

$$\alpha_{\text{E}} = \arccos(e^{-\text{TR}/T_1})$$

Animal experiments were conducted in accordance with the procedures approved by the Animal Welfare Department of the State Office for Health and Social Affairs Berlin (LAGeSo) and conformed to guidelines to minimize discomfort to animals (86/609/EEC).

The same molar concentrations of TF (12.15 mg/mL) and $\text{SF}_5\text{-TF}$ (10 mg/mL) suspended in 0.6% carboxymethyl cellulose were administered orally (bolus volume of 800 μL) to an anesthetized (intraperitoneal injection, 7.5 mg/kg of xylazine and 100 mg/kg of ketamine in NaCl) C57BL/6N mouse. After 20 min, the animal was sacrificed by an overdose of the anesthetic, the esophagus and duodenum were closed with a surgical suture, and the stomach was

removed. An ex vivo phantom was prepared in a 5 mL tube filled with 4% paraformaldehyde (Santa Cruz Biotechnology). We used RARE for anatomical ^1H MRI of the stomach: TR/TE = 2000 ms/10 ms; TA = 1 min, 4 s; FOV = $[28 \times 28]$ mm², and matrix = 256×256 , slice thickness = 0.5 mm, and an optimized UTE sequence for ^{19}F MRI of TF and $\text{SF}_5\text{-TF}$: TR/TE = 100 ms/0.27 ms; TA = 2 h, 30 min, slice thickness = 5 mm, $\text{FA}_{\text{TF}} = 25^{\circ}$, $\text{FA}_{\text{SF}_5\text{-TF}} = 42^{\circ}$, FOV = $[28 \times 28]$ mm², and matrix = 32×32 .

Data Analysis. For DHODH activity, time–absorbance curves reflect the enzymatic activity over time. We calculated the initial slope of these curves to quantify the initial velocity of the enzyme reaction. A Z' factor was calculated⁴⁰ using an in-house online Z' calculator to assess the quality of the screening method (<http://www.screeningunit-fmp.net/tools/z-prime.php>). Screening assays with Z' values between 0.5 and 1 are categorized as excellent.⁴⁰

For T cell proliferation, we analyzed flow cytometry data using FlowJo (software version 10.5.3, FlowJo LLC, Figure S2). The lymphocyte population was selected from the forward (FSC-A)/sideward scatter (SSC-A) and gated for single cells (FSC-A/FSC-H). Dead cells were excluded by gating for the cell population SSC-A/PI without PI staining. From this population, the CFSE-labeled cells were gated and displayed in a histogram, dividing the different generations of cells from cell divisions. The percentage of proliferating cells in relation to the originally labeled parental cell population was calculated.

A Z' factor (see the DHODH assay) was calculated from the number of proliferating cells in unstimulated negative and stimulated untreated positive controls. Additionally, the stimulation index (SI) was determined from the proportion of proliferating cells from non-proliferating ones

$$\text{SI} = \frac{\text{positive controls}}{\text{negative controls}}$$

Data from triplicates from each donor were combined so that each concentration point is represented by three measurement points.

MR image processing and spectral analysis and processing were performed in MATLAB R2018a (MathWorks, Inc.). MR data was analyzed as detailed in our previous work.⁴¹ Briefly, we quantified the spectral signal intensity, performed a Fourier transform to obtain magnitude spectra, and determined the chemical shift. We estimated the T_1 and T_2 time constants by fitting the measured signal intensities in MR magnitude images to the equations for T_1 and T_2 relaxations. SNR estimations for RARE, bSSFP, and UTE measurements and image preparation of ex vivo samples were performed as previously described.⁴² ImageJ⁴³ was used for further image analysis. We calculated the SNR efficiency (SNR/sqrt(time)) per mol to determine the compounds beneficial for in vivo application.

RESULTS AND DISCUSSION

Inhibitory Activity of TF Derivatives In Vitro. The trifluoromethoxy-substituted TF ($\text{CF}_3\text{O-TF}$) and pentafluor-*o*-sulfonyl-substituted TF ($\text{SF}_5\text{-TF}$) demonstrated equal or even better pharmacological and antiproliferative activities compared to TF ($\text{CF}_3\text{-TF}$) as shown by the IC_{50} values for DHODH inhibition in in vitro enzyme and proliferation assays (Table 1). We calculated the IC_{50} values for pharmacological DHODH inhibitory activity from dose–response curves and by fitting a dose–response model to the data points (Figure S3). The impact of TF and its derivatives to inhibit T cell proliferation was also determined from the IC_{50} values from dose–response curves and by fitting a dose–response model to the data points (Figure S3). The T cell stimulation index yielded 47.3.

For TF and its derivatives, we calculated the IC_{50} values and 95% confidence intervals, for both DHODH and T cell proliferation assays (Figure S3). The activity of $\text{CF}_3\text{O-TF}$ to inhibit DHODH was marginally higher than that of TF as shown by the lower IC_{50} , while that of $\text{SF}_5\text{-TF}$ was similar, and that of

Table 1. IC₅₀ Values and Confidence Intervals of the Enzyme Inhibition and Cell Proliferation Assays^a

compound	DHODH inhibition			cell proliferation inhibition		
	IC ₅₀ [μ M]	lower limit CI [μ M]	upper limit CI [μ M]	IC ₅₀ [μ M]	lower limit CI [μ M]	upper limit CI [μ M]
TF	0.54	0.32	0.77	24.25	19.01	29.52
CF ₃ O-TF	0.33	0.11	0.55	10.98	8.65	13.31
<i>di</i> -CF ₃ -TF	1.32	0.53	2.11	39.73	6.88	72.60
SF ₅ -TF	0.58	0.42	0.73	8.48	8.04	8.92

^aThe *Z'* value for the proliferation assay was 0.893, which is comparable to the *Z'* value obtained in the enzyme inhibition assay. A *Z'* value of >0.5 confirms the robustness of the assay. Therefore, unstimulated cells could be safely discriminated from stimulated controls.

the difluoromethyl-substituted *di*-CF₃-TF was lower (Figure S3 and Table 1). In T cell proliferation experiments, both CF₃O-TF and SF₅-TF showed a considerably greater inhibitory activity than TF, as shown by the dose–response curves (Figure S3B) and IC₅₀ values (Table 1). Compared to TF, SF₅-TF revealed the best inhibitory activity (IC₅₀ 8.48 μ M).

Substitution of the CF₃ group with a SF₅ group is expected to result in changes in the side chain geometry and electron density. The SF₅ group is characterized by a higher electronegativity and lipophilicity.¹⁹ The increased T cell inhibitory activity by SF₅-TF suggests an increased cellular uptake in T cells as a result of more efficient permeation through cell membranes due to increased lipophilicity, as has been shown in trypanothione reductase inhibitors exhibiting increased cellular activity and membrane permeability following introduction of SF₅.⁴⁴

We also performed a cell growth inhibition and cytotoxicity test in HepG2 cells (Supporting Information: Toxicology). All compounds showed a similar impact on cancer cell growth and cytotoxicity to that of TF (Figure S4). While T cell inhibitory activity of SF₅-TF was enhanced, its impact on cytotoxicity was similar to that of TF. Furthermore, nucleic acid staining using propidium iodide (PI) did not reveal cytotoxic effects in T cells, even at higher concentrations (Figure S5).

¹⁹F MR Relaxation and Chemical Shifts of TF Derivatives. We studied the ¹⁹F MR properties of all TF derivatives in DMSO and in human serum. We used serum to simulate the in vivo situation. When TF is administered to patients, it becomes strongly protein bound (e.g., in blood, it is >99% bound to protein⁴⁵). Since the solubility of TF compounds in serum was lower than in DMSO, lower concentrations of TF compounds were available in serum (Table S1); this resulted in an expected lower SNR (Figure S6). TF, CF₃O-TF, and *di*-CF₃-TF exhibit a single peak at –58, –55, and –59 ppm, respectively, in DMSO (Figure 2). SF₅-TF shows a main peak at 67.4 ppm and a smaller peak at 91.7 ppm at a ratio of 4:1 (Figure 2 and Figure S7). Due to the geometric orientation of the five fluorine atoms to the phenyl moiety, one positioned axially and four in equatorial positions, the main peak shows a line splitting (doublet) and the smaller peak shows an apparent 1:4:6:4:1 intensity pentet (Figure S7).⁴⁶

Spectra of the compounds solubilized in serum were similar to those in DMSO; although we observed a slight change in the chemical shift and peak broadening (Figure 2, lower panels), also quantified from the full width at half maximum (FWHM) of the peaks (Table S2).

Interestingly, increasing the number of fluorine atoms on a drug structure is not the only factor that affects the effective




Figure 2. ¹⁹F MR spectra of terflunomide and its derivatives. Signal acquired (normalized amplitudes) from compounds dissolved in DMSO (upper panels) or human serum (lower panels) obtained by a global single-pulse spectroscopy (TR = 1000 ms and TA = 8000 ms).

SNR. Our results indicate that addition of the SF₅-group to the molecular structure reduces both the transversal relaxation time *T*₂ and longitudinal relaxation time *T*₁.

Spin–lattice relaxation times (*T*₁) were measured for all TF derivatives (Table 2). Compared to TF in DMSO, *di*-CF₃-TF

Table 2. Comparison of *T*₁ and *T*₂ Relaxation Times in DMSO and Serum of TF and Its Derivatives to Optimize the SNR Efficiency of the ¹⁹F MR Acquisition Method

compound	<i>T</i> ₁ (ms)		<i>T</i> ₂ (ms)	
	DMSO	serum	DMSO	serum
TF	1003	1017	508	5
CF ₃ O-TF	1666	753	942	8
<i>di</i> -CF ₃ -TF	1098	875	642	5
SF ₅ -TF	371	331	68	6

had an almost equal *T*₁ relaxation time, CF₃O-TF had a prolonged *T*₁ relaxation time, and SF₅-TF had a substantially reduced *T*₁ relaxation time. In serum, *T*₁ was equal for TF but was reduced for CF₃O-TF, *di*-CF₃-TF, and SF₅-TF, compared to the same compounds in DMSO.

Spin–spin relaxation times (*T*₂) were also measured for all compounds (Table 2). Compared to TF in DMSO, CF₃O-TF and *di*-CF₃-TF had longer spin–spin relaxations, while SF₅-TF had a markedly shorter spin–spin relaxation. The *T*₂ in serum also dramatically dropped to values between 5 and 8 ms.

While a reduction in *T*₂ requires MR methods with faster signal acquisition (e.g., UTE), a reduction in *T*₁ reduces the time required between different excitations, thereby enabling more efficient data acquisition. The reductions in relaxation times could be attributed to dipole–dipole interactions and chemical shift anisotropy.^{47,48} Besides modifications of side chains, the addition of a paramagnetic dopant such as lanthanide chelates, in particular, gadolinium-containing contrast agents, has been used for shortening the *T*₁.⁴⁹ For ¹⁹F MR applications, ¹⁹F nanoparticles were functionalized with Gd(III) complexes for modulating the ¹⁹F signal.⁵⁰ Increased ¹⁹F MR signals from ¹⁹F nanoparticles were observed in close proximity to blood–brain barrier disruptions, indicating a *T*₁ shortening effect not only for

^1H but also for ^{19}F as a result of the paramagnetic contrast agent Gd–DTPA leakage.⁵¹

Impact of Serum on ^{19}F MR Relaxation. Differences in chemical shifts and relaxation times can be attributed to the different physicochemical properties of the ^{19}F groups. These properties were also severely affected by the serum environment. $\text{SF}_5\text{-TF}$ is administered as a suspension, and SF_6 is administered as a gas. All six fluorines on SF_6 produce one signal, whereas the SF_5 group has an AX4 spin system and produces two separate signals. Most notably, the ^{19}F T_2 relaxation times of TF and its derivatives were drastically shortened in serum. The increase in FWHM of the ^{19}F MR spectra in the serum compared to DMSO also suggests a T_2^* shortening.⁵² The observed shortening in relaxation is presumably attributed to unspecific binding of the compounds to serum proteins.⁵³ Similar to SF_5 -substituted TF, the fluorinated gas SF_6 exhibits a short transversal relaxation time.²⁰ SF_5 is an organic derivative of SF_6 in which one of the fluorine atoms is replaced by an organic residue. However, there are notable T_1 and T_2 differences between $\text{SF}_5\text{-TF}$ and SF_6 .^{20,21} At 9.4 T, the T_1 of SF_6 at room temperature (300 K) was reported to be <200 ms²¹ and is even shorter (1.24 ms at 1.9 T) when administered to rats as a gas (80%, 630 Torr barometric pressure).²⁰ The T_1 of $\text{SF}_5\text{-TF}$ was not strongly reduced in the presence of serum (Table 2), and we would expect similar values for this compound in vivo. On the other hand, the T_2 of $\text{SF}_5\text{-TF}$ was strongly reduced (by 90%) in the presence of serum. Differences between $\text{SF}_5\text{-TF}$ and SF_6 with respect to T_1 and T_2 can be attributed to differences in chemical environments.²³

Recently, we could detect TF in vivo when employing ^{19}F MRS.¹⁶ The above limitations in relaxation times, particularly when protein bound, restrict SNR. Due to the associated rapid loss in ^{19}F signal during T_2 relaxation, signal detection with ^{19}F MRI is expected to be more challenging.

Optimization of ^{19}F MR Parameters. We used the determined ^{19}F relaxation times for TF and its derivatives to calculate the most efficient parameters for three ^{19}F MRI acquisition methods: rapid acquisition with relaxation enhancement (RARE), balanced steady-state free precession (SSFP), and ultrashort echo time (UTE) (Table S3). Selection of the appropriate MR acquisition method according to the MR properties of the compound within a specific environment is essential to acquire data with the best SNR efficiency. A thorough characterization of ^{19}F compounds⁴¹ is typically necessary to adapt SNR efficient ^{19}F MR acquisition methods to the specific MR characteristics of these compounds.³⁸

We acquired ^{19}F MR images of all compounds using the corresponding optimized sequences (Figure S6) and compared SNR efficiencies (SNR per molecule divided by the square root of the acquisition time) to identify the most suited method for each compound, in DMSO and in serum (Table 3). In DMSO,

Table 3. SNR Comparison Using Optimized RARE, bSSFP, and UTE Protocols Studying the SNR Efficiency of Compounds (Using SNR per Molecule) in DMSO and in Serum (in % Normalized to TF RARE)

compound	RARE		bSSFP		UTE	
	DMSO	serum	DMSO	serum	DMSO	serum
TF	100	100	63	9	17	163
$\text{CF}_3\text{O-TF}$	106	101	55	20	14	148
<i>di</i> - $\text{CF}_3\text{-TF}$	200	162	130	34	33	240
$\text{SF}_5\text{-TF}$	68	76	74	26	32	363

RARE yielded the best SNR efficiency for all compounds, followed by bSSFP and UTE. In DMSO, *di*- $\text{CF}_3\text{-TF}$ showed the best SNR efficiency performance compared to TF. In serum, UTE was the MR acquisition method that provided the best SNR efficiency for all TF compounds, particularly for $\text{SF}_5\text{-TF}$. The SF_5 -substituted derivative showed a gain in ^{19}F SNR efficiency of ~ 3 compared to TF when using the UTE ^{19}F MRI method. This translates into a 9-fold reduction in measurement time, which is the primary obstacle of ^{19}F MRI for both clinical and preclinical applications. In addition, the $\text{SF}_5\text{-TF}$ also showed an increase of ~ 3 in inhibiting T cell proliferation.

One interpretation of these results is that the increased activity of $\text{SF}_5\text{-TF}$ could allow a lower dose to be used while maintaining the same level of therapeutic efficacy. However, a randomized clinical study following 12–14 years of TF treatment showed that a larger proportion of MS patients (51.5%) were relapse-free when receiving 14 mg of teriflunomide, compared to those receiving 7 mg of TF (39.5%).^{54,55} Thus, the higher efficacy of $\text{SF}_5\text{-TF}$ might have downstream benefits for MS patients, and future in vivo experiments in the animal model will be needed to clarify whether $\text{SF}_5\text{-TF}$ administered at the same dose as TF will be more efficacious at treating neurological diseases. Apart from a $\sim 3\times$ gain in the ^{19}F SNR efficiency in vitro, we observed an SNR gain of ~ 2 for $\text{SF}_5\text{-TF}$ compared to TF in the stomach ex vivo. This variation in the SNR gain could reflect variations in pH in the stomach that could affect relaxation times of TF.¹⁶ Future comparative studies are needed to focus on organ systems more relevant to the pathophysiology of MS such as the CNS.

Biological and ^{19}F MR Reporter Activities of TF Compounds. We aligned the biological activity with SNR efficiency of all ^{19}F MRI acquisition methods when comparing TF with its substituted derivatives (Figure 3A). Compared to all compounds, $\text{SF}_5\text{-TF}$ showed a clear enhancement in the T cell proliferation inhibitory activity, as well as SNR efficiency under serum conditions when using a UTE sequence. We administered TF and $\text{SF}_5\text{-TF}$ orally to C57BL/6 mice using the same molar concentrations (TF = 12.15 mg/mL ($n = 3$) and $\text{SF}_5\text{-TF} = 10$ mg/mL ($n = 3$)) and acquired ^{19}F MR images of the stomachs ex vivo using the optimized parameters (Figure 3B,C). We observed a clear distribution of both TF and $\text{SF}_5\text{-TF}$ in the stomach and measured peak SNR values of 13.2 ± 1.2 (mean \pm maximum absolute deviation) for $\text{SF}_5\text{-TF}$ in the stomach, compared to 5.8 ± 2.9 for TF (MR Characterization, Figure S8 and Table S4).

CONCLUSIONS

In this study, we introduced modifications, including those of SF_5 , to a pharmacologically active compound, to increase detection in vivo. To our knowledge, this is the first study that has performed an in-depth investigation of ^{19}F modifications on pharmacological and biological activities, alongside the MR reporter function. Here, we addressed SNR by modifying the CF_3 side chain of TF to vary the ^{19}F MR properties and identify potential SNR-boosting derivatives. Substituting the CF_3 side chain by CF_3O , SF_5 , or *di*- CF_3 did not compromise the pharmacological and antiproliferative activities. Of note, the superiority of the SF_5 -substituted derivative to inhibit T cell proliferation compared to TF indicates that some fluorination strategies might even improve the biological function.

Our study indicates SF_5 as a potential theranostic marker for detecting and studying the biodistribution of fluorinated drugs noninvasively, particularly during pathology. However, in vivo




Figure 3. Biological and ¹⁹F MR reporter activities of TF compounds. (A) Selecting the best ¹⁹F TF derivative and corresponding MR acquisition method. Drug compounds with the best inhibitory capacity (inverse IC₅₀ normalized to TF in percentage) and best SNR efficiency in serum (normalized to TF in percentage using a RARE sequence) obtained using RARE, bSSFP, and UTE sequences are shown in the upper right quadrant (orange region). (B) ¹⁹F MR reporter activity of TF in the stomach of a C57BL/6 mouse ex vivo using an optimized ¹⁹F UTE MR sequence. Left panel: ¹H anatomical image of the stomach, middle panel: ¹⁹F MRI of TF in the stomach, and right panel: ¹⁹F/¹H overlay. ¹H: RARE (TR/TE = 2000 ms/10 ms, TA = 1 min, 4 s) and ¹⁹F: UTE (TR/TE = 100 ms/0.27 ms, TA = 2 h, 30 min, FA = 25 °). (C) ¹⁹F MR reporter activity of SF₅-TF in the stomach of a C57BL/6 mouse ex vivo using an optimized ¹⁹F UTE MR sequence. Left panel: ¹H anatomical image of the stomach, middle panel: ¹⁹F MRI of SF₅-TF in the stomach, and right panel: ¹⁹F/¹H overlay. ¹H: RARE (TR/TE = 2000 ms/10 ms, TA = 1 min, 4 s) and ¹⁹F: UTE (TR/TE = 100 ms/0.27 ms, TA = 2 h, 30 min, FA = 42 °). SNR is indicated by the color bars.

studies will now be necessary to study the versatility of the SF₅ bioisostere in combination with the UTE method for in vivo ¹⁹F MRI and to determine its superiority over teriflunomide to treat disease in the animal model of multiple sclerosis.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acssensors.1c01024>.

Supplemental methods and results (chemistry, flow cytometry, enzyme and T cell growth inhibition, toxicology, and MR characterization) (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Sonia Waiczies – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; orcid.org/0000-0002-9916-9572; Email: sonia.waiczies@mdc-berlin.de

Authors

Christian Prinz – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Ludger Starke – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Tizian-Frank Ramspoth – Medicinal Chemistry, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Janis Kerkerling – Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Vera Martos Riaño – Medicinal Chemistry, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Jérôme Paul – Medicinal Chemistry, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Martin Neuenschwander – Screening Unit, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Andreas Oder – Screening Unit, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Silke Radetzki – Screening Unit, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Siegfried Adelhoefer – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Paula Ramos Delgado – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Mariya Aravina – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Jason M. Millward – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Ariane Fillmer – Physikalisch-Technische Bundesanstalt (PTB), 10587 Berlin, Germany

Friedemann Paul – Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), 10117 Berlin, Germany

Volker Siffrin – Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Jens-Peter von Kries – Screening Unit, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Thoralf Niendorf – Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Experimental and Clinical Research Center, a joint cooperation between the Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

Marc Nazaré – Medicinal Chemistry, Leibniz-Institut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acssensors.1c01024>

Author Contributions

The manuscript was written through contributions from all authors. All authors have given approval to the final version of the manuscript.

Funding

This work was supported by funding from the Germany Research Council (DFG WA2804). This project has received funding in part (T.N. and J.M.M.) from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under grant agreement no. 743077 (ThermalMR).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Peter Schmieder (FMP) for supporting the NMR analysis of the compounds.

ABBREVIATIONS

¹⁹F, fluorine-19; 1H, hydrogen-1/proton; bSSFP, balanced steady-state free precession; CF₃, trifluoromethyl; CFSE, carboxyfluoresceinsuccinimidylester; DCIP, dichloroindophe- nol; DHODH, dihydroorotate dehydrogenase; DMSO, dimethylsulfoxide; FA, flip angle; FID, free induction decay; FOV, field of view; FWHM, full width at half maximum; IC₅₀, inhibitory concentration (50%); L-DHO, L-dihydroorotate; MR, magnetic resonance; MRI, magnetic resonance imaging; MS, multiple sclerosis; PBMCs, peripheral blood mononuclear cells; PSF, point-spread-function; RARE, rapid acquisition with relaxation enhancement; RF, radiofrequency; RT, room temperature; SF₅, pentafluorosulfanyl; SNR, signal-to-noise ratio; TA, acquisition time; TE, echo time; TF, teriflunomide; TR, repetition time; UTE, ultrashort echo time

REFERENCES

- (1) Ruiz-Cabello, J.; Barnett, B. P.; Bottomley, P. A.; Bulte, J. W. M. Fluorine 19F MRS and MRI in biomedicine. *NMR Biomed.* **2011**, *24*, 114–129.
- (2) Reid, D. G.; Murphy, P. S. Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism. *Drug Discovery Today* **2008**, *13*, 473–480.
- (3) Muller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition. *Science* **2007**, *317*, 1881–1886.
- (4) Wang, J.; Sanchez-Rosello, M.; Acena, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001–2011). *Chem. Rev.* **2014**, *114*, 2432–2506.
- (5) Niendorf, T.; Ji, Y.; Waiczies, S., Chapter 11 Fluorinated Natural Compounds and Synthetic Drugs. In *Fluorine Magnetic Resonance Imaging*, 1 ed.; Ahrens, E. T.; Flögel, U. Ed. Pan Stanford Publishing: 2016; pp. 311–344, DOI: 10.1201/9781315364605-12.
- (6) Wolf, W.; Present, C. A.; Waluch, V. 19F-MRS studies of fluorinated drugs in humans. *Adv. Drug Delivery Rev.* **2000**, *41*, 55–74.
- (7) Chen, H.; Viel, S.; Ziarelli, F.; Peng, L. 19F NMR: a valuable tool for studying biological events. *Chem. Soc. Rev.* **2013**, *42*, 7971–7982.
- (8) Bartusik, D.; Aebischer, D. 19F applications in drug development and imaging - a review. *Biomed. Pharmacother.* **2014**, *68*, 813–817.
- (9) Ahrens, E. T.; Helfer, B. M.; O'Hanlon, C. F.; Schirda, C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. *Magn Reson Med* **2014**, *72*, 1696–1701.
- (10) Kieger, A.; Wiester, M. J.; Procissi, D.; Parrish, T. B.; Mirkin, C. A.; Thaxton, C. S. Hybridization-induced "off-on" 19F-NMR signal probe release from DNA-functionalized gold nanoparticles. *Small* **2011**, *7*, 1977–1981.
- (11) Zhang, C.; Li, L.; Han, F. Y.; Yu, X.; Tan, X.; Fu, C.; Xu, Z. P.; Whittaker, A. K. Integrating Fluorinated Polymer and Manganese-Layered Double Hydroxide Nanoparticles as pH-activated 19F MRI Agents for Specific and Sensitive Detection of Breast Cancer. *Small* **2019**, *15*, No. e1902309.
- (12) Waiczies, H.; Lepore, S.; Drechsler, S.; Qadri, F.; Purfurst, B.; Sydow, K.; Dathe, M.; Kuhne, A.; Lindel, T.; Hoffmann, W.; Pohlmann, A.; Niendorf, T.; Waiczies, S. Visualizing brain inflammation with a shingled-leg radio-frequency head probe for 19F/1H MRI. *Sci. Rep.* **2013**, *3*, 1280.
- (13) Flögel, U.; Ding, Z.; Hardung, H.; Jander, S.; Reichmann, G.; Jacoby, C.; Schubert, R.; Schrader, J. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. *Circulation* **2008**, *118*, 140–148.
- (14) Yu, J. X.; Hallac, R. R.; Chiguru, S.; Mason, R. P. New frontiers and developing applications in 19F NMR. *Prog. Nucl. Magn. Reson. Spectrosc.* **2013**, *70*, 25–49.
- (15) Bolo, N. R.; Hode, Y.; Nedelec, J. F.; Laine, E.; Wagner, G.; Macher, J. P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. *Neuropsychopharmacology* **2000**, *23*, 428–438.
- (16) Prinz, C.; Starke, L.; Millward, J. M.; Fillmer, A.; Delgado, P. R.; Waiczies, H.; Pohlmann, A.; Rothe, M.; Nazare, M.; Paul, F.; Niendorf, T.; Waiczies, S. In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. *Theranostics* **2021**, *11*, 2490–2504.
- (17) Wiese, M. D.; Rowland, A.; Polasek, T. M.; Sorich, M. J.; O'Doherty, C. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. *Expert Opin Drug Metab Toxicol* **2013**, *9*, 1025–1035.
- (18) Waiczies, S.; Millward, J. M.; Starke, L.; Delgado, P. R.; Huelnhagen, T.; Prinz, C.; Marek, D.; Wecker, D.; Wissmann, R.; Koch, S. P.; Boehm-Sturm, P.; Waiczies, H.; Niendorf, T.; Pohlmann, A. Enhanced Fluorine-19 MRI Sensitivity using a Cryogenic Radio-frequency Probe: Technical Developments and Ex Vivo Demonstration in a Mouse Model of Neuroinflammation. *Sci. Rep.* **2017**, *7*, 9808.

- (19) Sowaileh, M. F.; Hazlitt, R. A.; Colby, D. A. Application of the Pentafluorosulfanyl Group as a Bioisosteric Replacement. *ChemMedChem* **2017**, *12*, 1481–1490.
- (20) Adolphi, N. L.; Kuethe, D. O. Quantitative mapping of ventilation-perfusion ratios in lungs by ^{19}F MR imaging of T1 of inert fluorinated gases. *Magn Reson Med* **2008**, *59*, 739–746.
- (21) Håkansson, P.; Javed, M. A.; Komulainen, S.; Chen, L.; Holden, D.; Hasell, T.; Cooper, A.; Lantto, P.; Telkki, V. V. NMR relaxation and modelling study of the dynamics of SF(6) and Xe in porous organic cages. *Phys. Chem. Chem. Phys.* **2019**, *21*, 24373–24382.
- (22) Couch, M. J.; Ball, I. K.; Li, T.; Fox, M. S.; Biman, B.; Albert, M. S. ^{19}F MRI of the Lungs Using Inert Fluorinated Gases: Challenges and New Developments. *J Magn Reson Imaging* **2019**, *49*, 343–354.
- (23) Bassetto, M.; Ferla, S.; Pertusati, F. Polyfluorinated groups in medicinal chemistry. *Future Med. Chem.* **2015**, *7*, 527–546.
- (24) Wolf, U.; Scholz, A.; Heussel, C. P.; Markstaller, K.; Schreiber, W. G. Subsecond fluorine- ^{19}F MRI of the lung. *Magn Reson Med* **2006**, *55*, 948–951.
- (25) Kuethe, D. O.; Caprihan, A.; Gach, H. M.; Lowe, I. J.; Fukushima, E. Imaging obstructed ventilation with NMR using inert fluorinated gases. *J. Appl. Physiol.* **2000**, *88*, 2279–2286.
- (26) Baumgartner, R.; Walloschek, M.; Kralik, M.; Gotschlich, A.; Tasler, S.; Mies, J.; Leban, J. Dual binding mode of a novel series of DHODH inhibitors. *J. Med. Chem.* **2006**, *49*, 1239–1247.
- (27) Bonomo, S.; Tosco, P.; Giorgis, M.; Lolli, M.; Fruttero, R. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors. *J. Mol. Model.* **2013**, *19*, 1099–1107.
- (28) Westphal, M. V.; Wolfstadter, B. T.; Plancher, J. M.; Gatfield, J.; Carreira, E. M. Evaluation of tert-butyl isosteres: case studies of physicochemical and pharmacokinetic properties, efficacies, and activities. *ChemMedChem* **2015**, *10*, 461–469.
- (29) Avrutov, I.; Gershon, N.; Liberman, A. Method for synthesizing leflunomide. Patent 2002, US20020022646A1
- (30) Frantz, D. E.; Weaver, D. G.; Carey, J. P.; Kress, M. H.; Dolling, U. H. Practical synthesis of aryl triflates under aqueous conditions. *Org. Lett.* **2002**, *4*, 4717–4718.
- (31) Palle, V. R.; Bhat, R. P.; Kaliappan, M.; Babu, J. R.; Shanmughasamy, R. A novel process for the preparation of teriflunomide. Patent 2016, WO 2016203410 A1
- (32) Sainas, S.; Pippione, A. C.; Giorgis, M.; Lupino, E.; Goyal, P.; Ramondetti, C.; Buccinnà, B.; Piccinini, M.; Braga, R. C.; Andrade, C. H.; Andersson, M.; Moritzer, A.-C.; Friemann, R.; Mensa, S.; Al-Kadaraghi, S.; Boschi, D.; Lolli, M. L. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds. *Eur. J. Med. Chem.* **2017**, *129*, 287–302.
- (33) Ladds, M.; van Leeuwen, I. M. M.; Drummond, C. J.; Chu, S.; Healy, A. R.; Popova, G.; Pastor Fernandez, A.; Mollick, T.; Darekar, S.; Sedimbi, S. K.; Nekulova, M.; Sachweh, M. C. C.; Campbell, J.; Higgins, M.; Tuck, C.; Popa, M.; Safont, M. M.; Gelebart, P.; Fandalyuk, Z.; Thompson, A. M.; Svensson, R.; Gustavsson, A. L.; Johansson, L.; Farnegardh, K.; Yngve, U.; Saleh, A.; Haraldsson, M.; D'Hollander, A. C. A.; Franco, M.; Zhao, Y.; Hakansson, M.; Walse, B.; Larsson, K.; Peat, E. M.; Pelechano, V.; Lunec, J.; Vojtesek, B.; Carmena, M.; Earnshaw, W. C.; McCarthy, A. R.; Westwood, N. J.; Arsenian-Henriksson, M.; Lane, D. P.; Bhatia, R.; McCormack, E.; Lain, S. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. *Nat. Commun.* **2018**, *9*, 1107.
- (34) Knecht, W.; Löffler, M. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. *Biochem. Pharmacol.* **1998**, *56*, 1259–1264.
- (35) Copeland, R. A.; Davis, J. P.; Dowling, R. L.; Lombardo, D.; Murphy, K. B.; Patterson, T. A. Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. *Arch. Biochem. Biophys.* **1995**, *323*, 79–86.
- (36) Li, L.; Liu, J.; Delohery, T.; Zhang, D.; Arendt, C.; Jones, C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. *J. Neuroimmunol.* **2013**, *265*, 82–90.
- (37) Lyons, A. B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. *J. Immunol. Methods* **2000**, *243*, 147–154.
- (38) Faber, C.; Schmid, F. Chapter 1 Pulse Sequence Considerations and Schemes. In *Fluorine Magnetic Resonance Imaging*, Ahrens, E. T.; Flögel, U. Ed. Pan Stanford Publishing: 2016; pp. 3–27, DOI: 10.1201/9781315364605-2.
- (39) Mastropietro, A.; De Bernardi, E.; Breschi, G. L.; Zucca, I.; Cametti, M.; Soffientini, C. D.; de Curtis, M.; Terraneo, G.; Mitrangolo, P.; Spreafico, R.; Resnati, G.; Baselli, G. Optimization of rapid acquisition with relaxation enhancement (RARE) pulse sequence parameters for ^{19}F -MRI studies. *J Magn Reson Imaging* **2014**, *40*, 162–170.
- (40) Zhang, J. H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen* **1999**, *4*, 67–73.
- (41) Prinz, C.; Delgado, P. R.; Eigentler, T. W.; Starke, L.; Niendorf, T.; Waiczies, S. Toward ^{19}F magnetic resonance thermometry: spin-lattice and spin-spin-relaxation times and temperature dependence of fluorinated drugs at 9.4 T. *MAGMA* **2019**, *32*, 51–61.
- (42) Starke, L.; Niendorf, T.; Waiczies, S. Data Preparation Protocol for Low Signal-to-Noise Ratio Fluorine- ^{19}F MRI. In *Preclinical MRI of the Kidney: Methods and Protocols*, Pohlmann, A.; Niendorf, T., Eds. Springer US: New York, NY, 2021; pp. 711–722.
- (43) Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; Tinevez, J. Y.; White, D. J.; Hartenstein, V.; Eliceiri, K.; Tomancak, P.; Cardona, A. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **2012**, *9*, 676–682.
- (44) Stump, B.; Eberle, C.; Schweizer, W. B.; Kaiser, M.; Brun, R.; Krauth-Siegel, R. L.; Lentz, D.; Diederich, F. Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines. *ChemBioChem* **2009**, *10*, 79–83.
- (45) Warnke, C.; Stuve, O.; Kieseier, B. C. Teriflunomide for the treatment of multiple sclerosis. *Clin Neurol Neurosurg* **2013**, *115 Suppl 1*, S90–S94.
- (46) Dolbier, W. R., *Guide to fluorine NMR for organic chemists*. 2 ed.; Wiley: Hoboken, N.J., 2016.
- (47) Kadayakkara, D. K.; Damodaran, K.; Hitchens, T. K.; Bulte, J. W. M.; Ahrens, E. T. ^{19}F spin-lattice relaxation of perfluoropolyethers: Dependence on temperature and magnetic field strength (7.0–14.1T). *J. Magn. Reson.* **2014**, *242*, 18–22.
- (48) Dalvit, C.; Vulpetti, A. Fluorine-protein interactions and (1)(^{19}F) NMR isotropic chemical shifts: An empirical correlation with implications for drug design. *ChemMedChem* **2011**, *6*, 104–114.
- (49) Aime, S.; Botta, M.; Fasano, M.; Terreno, E. Lanthanide(III) chelates for NMR biomedical applications. *Chem. Soc. Rev.* **1998**, *27*, 19–29.
- (50) de Vries, A.; Moonen, R.; Yildirim, M.; Langereis, S.; Lamerichs, R.; Pikkemaat, J. A.; Baroni, S.; Terreno, E.; Nicolay, K.; Strijkers, G. J.; Grull, H. Relaxometric studies of gadolinium-functionalized perfluorocarbon nanoparticles for MR imaging. *Contrast Media Mol. Imaging* **2014**, *9*, 83–91.
- (51) Nöth, U.; Morrissey, S. P.; Deichmann, R.; Jung, S.; Adolf, H.; Haase, A.; Lutz, J. Perfluoro-15-Crown-5-Ether Labelled Macrophages in Adoptive Transfer Experimental Allergic Encephalomyelitis. *Artif Cells Blood Substit Immobil Biotechnol* **1997**, *25*, 243–254.
- (52) Jansen, J. F. A.; Backes, W. H.; Nicolay, K.; Kooi, M. E. ^1H MR spectroscopy of the brain: absolute quantification of metabolites. *Radiology* **2006**, *240*, 318–332.
- (53) Dubois, B. W.; Evers, A. S. Fluorine- ^{19}F NMR spin-spin relaxation (T_2) method for characterizing volatile anesthetic binding to proteins. Analysis of isoflurane binding to serum albumin. *Biochemistry* **1992**, *31*, 7069–7076.

(54) Kremenutzky, M.; Freedman, M.; Bar-Or, A.; Dukovic, D.; Benamor, M.; Truffinet, P.; Connor, P. 12-Year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study (P7.223). *Neurology* **2015**, *84*, P7.223.

(55) Freedman, M. S.; Bar-Or, A.; Benamor, M.; Truffinet, P.; Poole, E.; Mandel, M.; Kremenutzky, M. Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension Study (P6.389). *Neurology* **2018**, *90*, P6.389.